

Rubius Therapeutics Logo

## Rubius Therapeutics to Participate in Jefferies London Healthcare Conference

November 6, 2018

CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company developing an entirely new class of allogeneic cellular therapies, announced today that Pablo J. Cagnoni, M.D., chief executive officer, will present at Jefferies London Healthcare Conference Thursday, November 15, 2018, at 1:20 p.m. GMT.

A live audio webcast will be available within the [Investors & Media](#) section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event.

### About Rubius Therapeutics

Rubius Therapeutics is a biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company's proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready-to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius' initial focus is to advance RCT™ product candidates for the treatment of rare diseases, cancer and autoimmune diseases by leveraging three distinct therapeutic modalities — cellular shielding, potent cell-cell interaction and tolerance induction. For more information, visit [www.rubiustx.com](http://www.rubiustx.com), or follow us on [Twitter](#) and [LinkedIn](#).

### Media Contact:

Dan Budwick  
1AB, Inc.  
+1 (973) 271-6085  
[dan@1abmedia.com](mailto:dan@1abmedia.com)

### Investor Contact:

Lori Melançon  
Vice President, Corporate Communications and Investor Relations  
+1 (617) 229-6122  
[lori.melancon@rubiustx.com](mailto:lori.melancon@rubiustx.com)



Source: Rubius Therapeutics